Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zaharieva, Irina T ^a   Calissano, Mattia ^a   Scoto, Mariacristina ^a   Preston, Mark ^b   Cirak, Sebahattin ^a,c   Feng, Lucy ^a   Collins, James ^d   Kole, Ryszard ^e   Guglieri, Michela ^f   Straub, Volker ^f   Bushby, Kate ^f   Ferlini, Alessandra ^g   Morgan, Jennifer E ^a   Muntoni, Francesco ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Children's National Medical Centre   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e AVI BIOPHARMA INC   (United States)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MIRN1 MICRORNA, HUMAN; MIRN133 MICRORNA, HUMAN; MIRN206 MICRORNA, HUMAN; MIRN31 MICRORNA, HUMAN;

BLOOD; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; GENETICS; HUMAN; MUSCLE WEAKNESS; UPREGULATION;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MICRORNAS; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY, DUCHENNE; UP-REGULATION;

EID: 84894279286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080263     Document Type: Article

References (38)

1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, et al. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71: 304-13.
2. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L (2013) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet doi: 10.1038/ejhg.2012.301.
3. Bushby KM, Thambyayah M, Gardner-Medwin D (1991) Prevalence and incidence of Becker muscular dystrophy. Lancet 337: 1022-4.
4. Manzur AY, Kinali M, Muntoni F (2008) Update on the management of Duchenne muscular dystrophy. Arch Dis Child 93: 986-90.
5. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F (2005) Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 62: 809-23. (Pubitemid 40655631)
6. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, et al. (2007) Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 104: 17016-21. (Pubitemid 350210983)
7. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, et al. (2012) Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 14: R34.
8. Li YQ, Zhang MF, Wen HY, Hu CL, Liu R, et al. (2013) Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo) 68: 75-80.
9. Cacchiarelli D, Legnini I, Martone J, Cazzella V, D'Amico A, et al. (2011) miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 3: 258-65.
10. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, et al. (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38: 228-33. (Pubitemid 43177239)
11. Koutsoulidou A, Mastroyiannopoulos NP, Furling D, Uney JB, Phylactou LA (2011) Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle. BMC Dev Biol 11: 34.
12. Morgan JE, Partridge TA (2003) Muscle satellite cells. Int J Biochem Cell Biol 35: 1151-6. (Pubitemid 36577304)
13. Liu N, Williams AH, Maxeiner JM, Bezprozvannaya S, Shelton JM, et al. (2012) microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Invest 122: 2054-65.
14. Cacchiarelli D, Incitti T, Martone J, Cesana M, Cazzella V, et al. (2011) miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep 12: 136-41.
15. Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, et al. (2009) Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 23: 3335-46.
16. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, et al. (2011) Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One 6: e18388.
17. Roberts T, Blomberg E, McClorey G, EL Andaloussi S, Godfrey C, et al. (2012) Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy. Mol Ther Nucleic Acids 1: e39.
18. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-28.
19. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
20. Vignier N, Amor F, Fogel P, Duvallet A, Poupiot J, et al. (2013) Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies. PLoS One 8: e55281
21. Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, et al. (2010) Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol 25: 1559-81.
22. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, et al. (2005) Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26: 768-71. (Pubitemid 43130167)
23. Finsterer J, Stöllberger C (2003) The heart in human dystrophinopathies. Cardiology 99, 1-19. (Pubitemid 36206630)
24. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM (2001) Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 164: 2191-4. (Pubitemid 34032934)
25. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, et al. (2012) Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 84: 698-705.
26. Mendell JR, Moxley RT III, Griggs RC, Brooke MH, Fenichel GM, et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320: 1592-1597. (Pubitemid 19154573)
27. Bourke SC, Gibson GJ (2002) Sleep and breathing in neuromuscular disease. Eur Respir J 19: 1194-201. (Pubitemid 34649637)
28. rd Edition. Elsevier. pp.293-323.
29. R Mendell J, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol doi: 10.1002/ana.23982.
30. Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, et al. (2011) Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 19: 345-54
31. Paco S, Ferrer I, Jou C, Cusí V, Corbera J, et al. (2012) Muscle fiber atrophy and regeneration coexist in collagen VI-deficient human muscle: role of calpain-3 and nuclear factor-κB signaling. J Neuropathol Exp Neurol 71: 894-906.
32. Bernardi P, Bonaldo P (2008) Dysfunction of mitochondria and sarcoplasmic reticulum in the pathogenesis of collagen VI muscular dystrophies. Ann N Y Acad Sci 1147: 303-11.
33. Grumati P, Coletto L, Sabatelli P, Cescon M, Angelin A, et al. (2010) Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat Med 16: 1313-20.
34. Grumati P, Coletto L, Sandri M, Bonaldo P (2011) Autophagy induction rescues muscular dystrophy. Autophagy 7: 426-8.
35. Boonen KJ, Rosaria-Chak KY, Baaijens FP, van der Schaft DW, Post MJ (2009) Essential environmental cues from the satellite cell niche: optimizing proliferation and differentiation. Am J Physiol Cell Physiol 296: C1338-45.
36. Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, et al. (2005) Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 14: 155-69. (Pubitemid 40123471)
37. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-8.
38. Ihaka R, Gentleman R (1996) R: A language for data analysis and graphics. J Comput Graph Stat 3: 299-314.